These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30939353)

  • 1. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
    Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
    Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
    Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
    Govek SP; Bonnefous C; Julien JD; Nagasawa JY; Kahraman M; Lai AG; Douglas KL; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2019 Feb; 29(3):367-372. PubMed ID: 30587451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.
    Wang L; Guillen VS; Sharma N; Flessa K; Min J; Carlson KE; Toy W; Braqi S; Katzenellenbogen BS; Katzenellenbogen JA; Chandarlapaty S; Sharma A
    ACS Med Chem Lett; 2018 Aug; 9(8):803-808. PubMed ID: 30128071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects.
    Lu Y; Liang Z; Liu L; Zhou Y; Liu C; Zhao Z; Zheng T; Du Q; Liu W
    Eur J Med Chem; 2024 Sep; 275():116534. PubMed ID: 38870830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells.
    Zheng Y; Wang C; Li C; Qiao J; Zhang F; Huang M; Ren W; Dong C; Huang J; Zhou HB
    Org Biomol Chem; 2012 Dec; 10(48):9689-99. PubMed ID: 23149805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
    Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
    J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
    Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
    J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.
    Ragab MA; Elagawany M; Daabees H; Ahmed AF; Awad EM; Billon C; Elgendy B; Abouzid KAM; Kassab SE
    Bioorg Chem; 2022 Feb; 119():105554. PubMed ID: 34923243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
    Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
    J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.
    Zheng Y; Zhu M; Srinivasan S; Nwachukwu JC; Cavett V; Min J; Carlson KE; Wang P; Dong C; Katzenellenbogen JA; Nettles KW; Zhou HB
    ChemMedChem; 2012 Jun; 7(6):1094-100. PubMed ID: 22517684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
    Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
    J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.